Enliven Therapeutics (ELVN) Enterprise Value (2019 - 2026)
Enliven Therapeutics (ELVN) reported Enterprise Value of -$452.4 million for Q1 2026, down 344.82% on a YoY basis from $184.8 million in Q1 2025, and up 2.21% sequentially from -$462.6 million in Q4 2025.
Enliven Therapeutics (ELVN) Enterprise Value (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Enterprise Value data on file, last reported at -$452.4 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 344.82% year-over-year to -$452.4 million; the trailing twelve-month figure through Mar 2026 stood at -$452.4 million (down 344.82% YoY), and the FY2025 full-year result was -$462.6 million, down 47.59% from the prior year.
- Enterprise Value climbed to -$452.4 million in Q1 2026, from -$462.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$75.5 million in Q4 2022 to a low of -$462.6 million in Q4 2025.
- A 5-year average of -$210.8 million and a median of -$136.3 million in 2022 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value surged 68.27% in 2025 and sank 344.82% in 2026, its largest moves.
- Tracing ELVN's Enterprise Value over 5 years: stood at -$75.5 million in 2022, then sank by 235.14% to -$253.1 million in 2023, then slipped by 23.82% to -$313.4 million in 2024, then slumped by 47.59% to -$462.6 million in 2025, then gained by 2.21% to -$452.4 million in 2026.
- Business Quant data shows ELVN's Enterprise Value at -$452.4 million in Q1 2026, -$462.6 million in Q4 2025, and -$101.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | -452.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -452.40 Mn |
| Dec 31, 2025 | -462.62 Mn |
| Sep 30, 2025 | -101.73 Mn |
| Jun 30, 2025 | -119.44 Mn |
| Mar 31, 2025 | -101.71 Mn |
| Dec 31, 2024 | -313.44 Mn |
| Sep 30, 2024 | -100.68 Mn |
| Jun 30, 2024 | -96.93 Mn |
| Mar 31, 2024 | -320.50 Mn |
| Dec 31, 2023 | -253.15 Mn |
| Sep 30, 2023 | -263.48 Mn |
| Jun 30, 2023 | -277.87 Mn |
| Mar 31, 2023 | -292.10 Mn |
| Dec 31, 2022 | -75.54 Mn |
| Sep 30, 2022 | -92.97 Mn |
| Jun 30, 2022 | -122.36 Mn |
| Mar 31, 2022 | -136.29 Mn |
| Dec 31, 2021 | -90.28 Mn |
| Sep 30, 2021 | -102.84 Mn |
| Jun 30, 2021 | -66.77 Mn |